Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Gross Profit: 2022-2025

Historic Gross Profit for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $403,159.

  • InMed Pharmaceuticals' Gross Profit fell 18.29% to $403,159 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 2.75%. This contributed to the annual value of $1.7 million for FY2025, which is 55.02% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Gross Profit is $403,159, which was down 30.09% from $576,654 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Gross Profit registered a high of $1.6 million during Q2 2023, and its lowest value of -$491,018 during Q3 2022.
  • Moreover, its 3-year median value for Gross Profit was $403,159 (2025), whereas its average is $452,141.
  • The largest annual percentage gain for InMed Pharmaceuticals' Gross Profit in the last 5 years was 2,222.82% (2024), contrasted with its biggest fall of 70.32% (2024).
  • Over the past 4 years, InMed Pharmaceuticals' Gross Profit (Quarterly) stood at $131,163 in 2022, then spiked by 147.13% to $324,142 in 2023, then spiked by 42.19% to $460,894 in 2024, then decreased by 18.29% to $403,159 in 2025.
  • Its Gross Profit stands at $403,159 for Q3 2025, versus $576,654 for Q2 2025 and $175,625 for Q1 2025.